Sigrid S. Skånland
- Project group leader, Lab leader and Researcher; PhD
- +47 2278 1981
Room: K06.116
Shipping address
Oslo University Hospital
Institute for Cancer Research, Building K
Department of Cancer Immunology, Room K03.001
Ullernchausseen 70
0379 Oslo, Norway
ORCID: Sigrid Skånland
Twitter/X: @SigridSkanland
LinkedIn: www.linkedin.com/in/sigrid-skanland
Sigrid Skånland's project group: https://www.ous-research.no/skanland group
Biography
Sigrid S. Skånland received her PhD from the Faculty of Mathematics and Natural Sciences at University of Oslo in 2009, under the supervision of Prof. Kirsten Sandvig. She was then awarded with a long-term EMBO fellowship to do her post-doctoral training in the Molecular Signaling Group of Prof. Ivan Dikic (2009-2011) at the University Hospital Frankfurt, Germany. From 2011, Skånland has been affiliated with the research group of Prof. Kjetil Taskén, first at the Nordic EMBL Partnership for Molecular Medicine in Norway (NCMM), currently at Oslo University Hospital. Here, she has established her own research group focusing on functional precision medicine in haematologic cancers, in particular the B-cell malignancy chronic lymphocytic leukemia. By performing functional analyses including ex vivo drug sensitivity screening and single cell signaling analyses, her aim is to identify biomarker signatures that can predict treatment outcomes for the individual patient. In 2020, Skånland became coordinator of the European Commission ERA PerMed consortium CLL-CLUE on tailoring the targeted treatment of chronic lymphocytic leukemia, and in 2023 she was awarded "Researcher of the year" at the Institute for Cancer Research.
Curriculum Vitae
Education
2009 PhD “Mechanisms in intracellular transport of toxins.”
The Norwegian Radium Hospital, University of Oslo, NO
Supervisor: Prof. Kirsten Sandvig
2005 MSc “The phosphatidylinositol 3-kinase hVps34 modulates endosome to Golgi transport of ricin.”
The Norwegian Radium Hospital, University of Oslo, NO
Current positions
2022-present Researcher in The Norwegian Centre for Clinical Cancer Research (MATRIX)
2021-present Coordinator of the ERA PerMed consortium CLL-CLUE
2021-present Project group leader. Department of Cancer Immunology, Institute for Cancer Research
2018-present Researcher and Lab leader in Prof. Kjetil Taskén’s lab
Oslo University Hospital, Institute for Cancer Research, Oslo, NO
Previous positions
2017-2018 Lab leader in Prof. Kjetil Taskén’s lab
Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, NO
2015-2018 Senior Researcher in Prof. Kjetil Taskén’s lab
NCMM, Nordic EMBL Partnership, University of Oslo, NO
2011-2015 Postdoc in Prof. Kjetil Taskén’s lab
NCMM, Nordic EMBL Partnership, University of Oslo, NO
2009-2011 EMBO fellow/Postdoc in Prof. Ivan Dikic’s lab
Institute of Biochemistry II, Goethe University School of Medicine, DE
Fellowships and Awards
2023 Researcher of the Year 2023 (100 000 NOK), Institute for Cancer Research
2023 Excellent Research Article 2022 (50 000 NOK), Oslo University Hospital
2022 Fondsstiftelsen (400 000 NOK)
2022 Prize for best article 2022, K.G. Jebsen Centre for B-cell Malignancies
2021-present ERA PerMed cofunded by the European Comission (coordinator) (1.5 mEUR)
2019 Legacy: Lilly Constance og Karl Ingolf Larssons stiftelse (400 000 NOK)
2015-2019 Career Development Research Fellowship, The Norwegian Cancer Society
2012 Legacy: Ella og Kristian Nyerrøds stiftelse for medisinsk forskning ved Universitetet i Oslo
2009-2011 EMBO Long-term fellowship
Mobility
2022 Sabbatical (5 months) in Dr. Omar Abdel-Wahab's lab
Memorial Sloan Kettering Cancer Center, New York, NY, USA
2019 Visiting scientist (1 month) in Dr. Adrian Wiestner's lab
NIH, Bethesda, MD, USA
2009-2011 EMBO fellow/Postdoc in Prof. Ivan Dikic’s lab
Institute of Biochemistry II, Goethe University School of Medicine, DE
2006 Visiting student (3 months) in Prof. Tom A. Rapoport’s lab
Harvard Medical School, Boston, MA, USA
Supervision and teaching
2015-present 3 Postdocs, 1 researcher, 4 PhD fellows, 1 MD/PhD, 4 Master students, 1 UiO:Life Science internship
2024 MED3059 - Cancer research, University of Oslo, NO
2022 Cancer Genomics (PhD course), BRIC, University of Copenhagen, DK
2021-present BIOS9710 - Advanced cancer biology (PhD course), University of Oslo, NO
2020-present MF9135 - Biomarkers in clinical research (PhD course), University of Oslo, NO
2019-present MF9120BTS - Molecular Medicine (national PhD course), University of Oslo, NO
2009-2011 Laboratory practical courses. Goethe University School of Medicine, DE
Publications 2024
Immunophenotyping with (phospho)protein profiling and fluorescent cell barcoding for single-cell signaling analysis and biomarker discovery
NPJ Precis Oncol, 8 (1), 107
DOI 10.1038/s41698-024-00604-y, PubMed 38769096
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Science, 383 (6682), eadi5798
DOI 10.1126/science.adi5798, PubMed 38301010
PI3K Inhibitors in Hematology: When One Door Closes…
Clin Cancer Res, 30 (17), 3667-3675
DOI 10.1158/1078-0432.CCR-24-0967, PubMed 38967552
Publications 2023
Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling
Cell Rep Methods, 3 (12), 100654
DOI 10.1016/j.crmeth.2023.100654, PubMed 38065095
Standardized assays to monitor drug sensitivity in hematologic cancers
Cell Death Discov, 9 (1), 435
DOI 10.1038/s41420-023-01722-5, PubMed 38040674
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
Cell Death Discov, 9 (1), 125
DOI 10.1038/s41420-023-01426-w, PubMed 37055391
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Haematologica, 108 (1), 9-21
DOI 10.3324/haematol.2022.281266, PubMed 35899388
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts
Blood, 141 (13), 1584-1596
DOI 10.1182/blood.2022016934, PubMed 36375120
Publications 2022
Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare)
Am J Hematol, 97 Suppl 2, S19-S25
DOI 10.1002/ajh.26682, PubMed 36125036
Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells
Methods Mol Biol, 2449, 327-348
DOI 10.1007/978-1-0716-2095-3_14, PubMed 35507270
Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models
Trends Pharmacol Sci, 43 (11), 973-985
DOI 10.1016/j.tips.2022.08.009, PubMed 36163057
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
Front Oncol, 12, 1040730
DOI 10.3389/fonc.2022.1040730, PubMed 36523963
Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
Mol Oncol, 16 (6), 1241-1258
DOI 10.1002/1878-0261.13191, PubMed 35148457
T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation
Br J Haematol, 198 (3), 556-573
DOI 10.1111/bjh.18285, PubMed 35655388
Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case
Haematologica, 107 (8), 1994-1998
DOI 10.3324/haematol.2021.280393, PubMed 35236056
Determining drug dose in the era of targeted therapies: playing it (un)safe?
Blood Cancer J, 12 (8), 123
DOI 10.1038/s41408-022-00720-7, PubMed 35999205
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Clin Cancer Res, 28 (20), 4444-4455
DOI 10.1158/1078-0432.CCR-22-1221, PubMed 35998013
Publications 2021
A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis
Sci Transl Med, 13 (582)
DOI 10.1126/scitranslmed.abb0036, PubMed 33627483
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
Mol Oncol, 16 (5), 1153-1170
DOI 10.1002/1878-0261.13153, PubMed 34861096
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Blood, 138 (18), 1768-1773
DOI 10.1182/blood.2021011841, PubMed 34297826
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
Blood Adv, 5 (1), 334-343
DOI 10.1182/bloodadvances.2020003423, PubMed 33570649
Publications 2020
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Blood, 136 (10), 1134-1143
DOI 10.1182/blood.2020006965, PubMed 32688395
B cell signalling pathways-New targets for precision medicine in chronic lymphocytic leukaemia
Scand J Immunol, 92 (5), e12931
DOI 10.1111/sji.12931, PubMed 32640099
Publications 2019
Off-label uses of drugs for depression
Eur J Pharmacol, 865, 172732
DOI 10.1016/j.ejphar.2019.172732, PubMed 31622593
An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL
Leukemia, 34 (2), 478-487
DOI 10.1038/s41375-019-0569-7, PubMed 31471562
Carboxyl-Terminal Src Kinase Binds CD28 upon Activation and Mutes Downstream Signaling
J Immunol, 203 (4), 1055-1063
DOI 10.4049/jimmunol.1801660, PubMed 31292214
Publications 2018
Cryopreservation of primary B cells minimally influences their signaling responses
Sci Rep, 8 (1), 17651
DOI 10.1038/s41598-018-36121-9, PubMed 30518828
Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia
Oncotarget, 9 (10), 9273-9284
DOI 10.18632/oncotarget.23949, PubMed 29507689
Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
J Vis Exp (140)
DOI 10.3791/58386, PubMed 30346411
In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy
Blood, 132, 4676
DOI 10.1182/blood-2018-99-110357, PublikaID 304
Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
Blood, 132, 4677
DOI 10.1182/blood-2018-99-110669, PublikaID 303
Publications 2015
Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells
Haematologica, 101 (2), e59-62
DOI 10.3324/haematol.2015.135590, PubMed 26589914
Publications 2014
T-cell co-stimulation through the CD2 and CD28 co-receptors induces distinct signalling responses
Biochem J, 460 (3), 399-410
DOI 10.1042/BJ20140040, PubMed 24665965
Publications 2013
BiP negatively affects ricin transport
Toxins (Basel), 5 (5), 969-82
DOI 10.3390/toxins5050969, PubMed 23666197
Publications 2012
Modulation of proximal signaling in normal and transformed B cells by transmembrane adapter Cbp/PAG
Exp Cell Res, 318 (14), 1611-9
DOI 10.1016/j.yexcr.2012.05.014, PubMed 22659621
Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells
Arterioscler Thromb Vasc Biol, 33 (2), e47-55
DOI 10.1161/ATVBAHA.112.253427, PubMed 23162017
Annexin A1 and A2: roles in retrograde trafficking of Shiga toxin
PLoS One, 7 (7), e40429
DOI 10.1371/journal.pone.0040429, PubMed 22792315
Publications 2011
SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis
Nature, 471 (7340), 637-41
DOI 10.1038/nature09814, PubMed 21455181
Publications 2010
Spatial organization of transmembrane receptor signalling
EMBO J, 29 (16), 2677-88
DOI 10.1038/emboj.2010.175, PubMed 20717138
Publications 2009
SNX4 in complex with clathrin and dynein: implications for endosome movement
PLoS One, 4 (6), e5935
DOI 10.1371/journal.pone.0005935, PubMed 19529763
β-arrestins attenuate p38-mediated endosome to Golgi transport
Cell Microbiol, 11 (5), 796-807
DOI 10.1111/j.1462-5822.2009.01292.x, PubMed 19159388
Characterization of clathrin and Syk interaction upon Shiga toxin binding
Cell Signal, 21 (7), 1161-8
DOI 10.1016/j.cellsig.2009.03.005, PubMed 19289168
Publications 2008
Mechanisms in intracellular transport of toxins
In Series of dissertations submitted to the Faculty of Mathematics and Natural Sciences, University of Oslo, The Faculty, Oslo, nr. 818, 1 b. (flere pag.)
BIBSYS 090016602
Publications 2007
Ribosome binding of a single copy of the SecY complex: implications for protein translocation
Mol Cell, 28 (6), 1083-92
DOI 10.1016/j.molcel.2007.10.034, PubMed 18158904
Phosphoinositide-regulated retrograde transport of ricin: crosstalk between hVps34 and sorting nexins
Traffic, 8 (3), 297-309
DOI 10.1111/j.1600-0854.2006.00527.x, PubMed 17319803
Protein kinase Cdelta is activated by Shiga toxin and regulates its transport
J Biol Chem, 282 (22), 16317-28
DOI 10.1074/jbc.M610886200, PubMed 17403690
SNX1 and SNX2 mediate retrograde transport of Shiga toxin
Biochem Biophys Res Commun, 358 (2), 566-70
DOI 10.1016/j.bbrc.2007.04.159, PubMed 17498660
The Mitogen-activated protein kinase p38 links Shiga Toxin-dependent signaling and trafficking
Mol Biol Cell, 19 (1), 95-104
DOI 10.1091/mbc.e07-06-0565, PubMed 17959827
Publications 2005
The PI 3-kinase hVps34 modulates endosomes to Golgi transport of ricin
S.S. Skånland, Oslo, 47, 23 s.
BIBSYS 050613553